These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effects of S-nitrosocaptopril on canine coronary circulation.
    Author: Nakae I, Takahashi M, Kinoshita T, Matsumoto T, Kinoshita M.
    Journal: J Pharmacol Exp Ther; 1995 Jul; 274(1):40-6. PubMed ID: 7616425.
    Abstract:
    Nitroglycerin (NTG) has been used for more than a century for the relief of angina pectoris and is regarded as an extrinsic donor of nitric oxide (NO). Captopril, an angiotensin-converting enzyme inhibitor (ACEI), is reported to have beneficial effects on survival in acute myocardial infarction. In this study, a hybrid compound of NO and ACEI, S-nitrosocaptopril (S-NO-Cap), was synthesized, which was characterized by its molecular structure. Its coronary effects in chronically instrumented dogs were compared with those of NTG and captopril. S-NO-Cap (50 micrograms/kg i.v.) increased epicardial coronary diameter (CoD) by a maximum of 5.2% for more than 20 min. NTG (15 micrograms/kg i.v.) increased CoD by a maximum of 4.6% for 10 min, i.e., the effect was equipotent with that of S-NO-Cap (50 micrograms/kg i.v.). However, S-NO-Cap produced its maximal CoD increase more slowly than NTG did. Both S-NO-Cap and NTG transiently increased coronary blood flow. However, NTG had a more potent effect than S-NO-Cap (28.4 vs. 40.8 ml/min, respectively). Captopril, on the other hand, had almost no effect on either CoD or coronary blood flow. Thus, the vasodilatory action of S-NO-Cap more closely resembled that of NTG than that of captopril. Therefore, S-NO-Cap may dilate coronary arteries by virtue of its NO moiety rather than by its ACEI properties. These findings indicate that S-NO-Cap is a potential antianginal drug.
    [Abstract] [Full Text] [Related] [New Search]